Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Barinthus Biotherapeutics plc before investing.

In this article, we go over a few key elements for understanding Barinthus Biotherapeutics plc’s stock price such as:

• Barinthus Biotherapeutics plc’s current stock price and volume
• Why Barinthus Biotherapeutics plc’s stock price changed recently
• Upgrades and downgrades for BRNS from analysts
• BRNS’s stock price momentum as measured by its relative strength

About Barinthus Biotherapeutics plc (BRNS)

Before we jump into Barinthus Biotherapeutics plc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.

Want to learn more about Barinthus Biotherapeutics plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Barinthus Biotherapeutics plc.

Barinthus Biotherapeutics plc’s Stock Price as of Market Close

As of July 31, 2026, 3:50 PM, CST, Barinthus Biotherapeutics plc’s stock price was $0.558.

Barinthus Biotherapeutics plc is up 0.14% from its previous closing price of $0.557.

During the last market session, Barinthus Biotherapeutics plc’s stock traded between $0.558 and $0.600. Currently, there are approximately 40.85 million shares outstanding for Barinthus Biotherapeutics plc.

Barinthus Biotherapeutics plc’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Barinthus Biotherapeutics plc Stock Price History

Barinthus Biotherapeutics plc’s (BRNS) price is currently down 15.48% so far this month.

During the month of July, Barinthus Biotherapeutics plc’s stock price has reached a high of $0.700 and a low of $0.540.

Over the last year, Barinthus Biotherapeutics plc has hit prices as high as $1.830 and as low as $0.512. Year to date, Barinthus Biotherapeutics plc’s stock is down 20.33%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Barinthus Biotherapeutics plc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Barinthus Biotherapeutics plc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Barinthus Biotherapeutics plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Barinthus Biotherapeutics plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Barinthus Biotherapeutics plc’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Barinthus Biotherapeutics plc (BRNS) by visiting AAII Stock Evaluator.

Relative Price Strength of Barinthus Biotherapeutics plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Barinthus Biotherapeutics plc has a weighted four-quarter relative price strength of -22.00%, which translates to a Momentum Score of 11 and is considered to be Very Weak.

Want to learn more about how Barinthus Biotherapeutics plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Barinthus Biotherapeutics plc Stock Price: Bottom Line

As of July 31, 2026, Barinthus Biotherapeutics plc’s stock price is $0.558, which is up 0.14% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Barinthus Biotherapeutics plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.